The Company revised the following amounts in the consolidated statements of operations and comprehensive income (loss), the consolidated balance sheets and the consolidated statements of changes in stockholders’ equity, as applicable, originally reported in the Form 10-K for the annual period ended December 31, 2024, in this Annual Report on Form 10-K for the year ended December 31, 2025:


Consolidated Statements of Operations and Comprehensive Loss — Year Ended December 31, 2024	As Previously Reported		Adjustments		As Adjusted
Selling, general and administrative expense	$	340,894	$	2,904	$	343,798
Research and development expense	13,639		312		13,951
Operating loss	(11,979)		(3,216)		(15,195)
Loss before income taxes	(49,126)		(3,216)		(52,342)
Net loss	(43,833)		(3,216)		(47,049)
Loss attributable to noncontrolling interest	10,291		633		10,924
Net loss attributable to Bioventus Inc.	(33,542)		(2,583)		(36,125)
Comprehensive loss	(48,014)		(3,216)		(51,230)
Comprehensive loss attributable to noncontrolling interest	11,105		633		11,738
Comprehensive loss attributable to Bioventus Inc.	(36,909)		(2,583)		(39,492)
Loss per share of Class A common stock - basic and diluted	$	(0.52)	$	(0.04)	$	(0.56)


Consolidated Balance Sheets — December 31, 2024	As Previously Reported		Adjustments		As Adjusted
Additional paid in capital	$	505,509	$	2,583	$	508,092
Accumulated deficit	(355,078)		(2,583)		(357,661)